Free Trial
→ A new income category is drawing serious money - here's why (From Investors Alley) (Ad)tc pixel
NASDAQ:ENTX

Entera Bio Q4 2024 Earnings Results & Report

Entera Bio logo
$2.50 +0.02 (+0.60%)
Closing price 03:59 PM Eastern
Extended Trading
$2.50 0.00 (0.00%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Entera Bio beat analyst earnings expectations and met on revenue in its Q4 2024 results, released March 28, 2025. The company reported EPS of -$0.06 versus the -$0.08 consensus estimate, while revenue of $0.04 million matched the $0.04 million estimate.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q4 2024
Report Date
Time
Before Market Opens
Conference Call Date
Conference Call
7:00 PM ET

Entera Bio EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.08
Beat/Miss
Beat by +$0.02
One Year Ago EPS
N/A
EPS Beat Rate
6 of last 8 quarters

Entera Bio Revenue Results

Actual Revenue
$0.04 million
Expected Revenue
$0.04 million
Beat/Miss
Met Expectations
YoY Revenue Growth
N/A

Upcoming Earnings

Entera Bio's Q3 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules, with a conference call scheduled on Friday, November 6, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Conference Call Resources

Powered by Quartr

Earnings Documents

Entera Bio's Q4 2024 Press ReleasePress Release
(8-K)
Entera Bio's Q4 2024 Annual reportAnnual report
(10-K)

Entera Bio Q4 2024 Earnings FAQ

Entera Bio (NASDAQ:ENTX) reported earnings of -$0.06 per share for Q4 2024, beating the consensus estimate of -$0.08. The report was announced on Friday, March 28, 2025.

Entera Bio reported revenue of $0.04 million for Q4 2024, against a consensus estimate of $0.04 million.

Entera Bio's next earnings date is estimated for Friday, November 13, 2026. MarketBeat tracks confirmed and estimated earnings dates for Entera Bio on the company's earnings history page.

Entera Bio Earnings Headlines

Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and ...
October 13 at 7:30 AM  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/entera-presents-markedly-enhanced-anabolic-effects-of-eb613-first-in-class-oral-pth-1-34-tablet-in-postmenopausal-women-with-osteoporosis-at-high-risk-of-fracture-and-showcases-phase-3-design-at-1036620235
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
October 13 at 7:00 AM  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/13/3379518/0/en/entera-presents-markedly-enhanced-anabolic-effects-of-eb613-first-in-class-oral-pth-1-34-tablet-in-postmenopausal-women-with-osteoporosis-at-high-risk-of-fracture-and-showcases-pha.html
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.tc pixel
October 14 at 1:00 AM  |  Banyan Hill Publishing (Ad)
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
October 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/08/3377187/0/en/entera-bio-announces-additional-presentation-of-eb613-phase-3-study-design-at-the-asbmr-2026-annual-meeting.html
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
October 6, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/entera-appoints-global-biopharma-executive-laura-hamill-to-its-board-of-directors-expanding-commercial-expertise-1036600623
ENTX - Entera Bio
September 27, 2026  |  br.investing.comhttps://br.investing.com/equities/entera-bio-ltd
See More Entera Bio Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Entera Bio? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Entera Bio and other key companies, straight to your email.

About Entera Bio

Entera Bio (NASDAQ:ENTX) is a clinical-stage biopharmaceutical company focused on developing orally delivered biologic medicines. The company’s proprietary platform is designed to enable the oral administration of large-molecule therapies, including peptides and proteins that are traditionally delivered by injection.

Entera Bio’s pipeline has included EB613, an oral formulation of parathyroid hormone fragment (teriparatide) being developed for the treatment of osteoporosis, and EB612, an oral parathyroid hormone product intended for hypoparathyroidism. The company’s technology is designed to protect biologic molecules in the gastrointestinal tract and facilitate their absorption.

Founded in 2010 and headquartered in Jerusalem, Israel, Entera Bio conducts its research and development activities through its Israeli operations and collaborates with pharmaceutical and biotechnology partners. The company’s programs are aimed at improving the convenience and potential accessibility of treatments that otherwise require injections.

View Entera Bio Profile
Earnings Tools